RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+88.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.13B
AUM Growth
+$5.13B
(+62%)
Cap. Flow
+$1.15B
Cap. Flow
% of AUM
22.34%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
66
New
18
Increased
9
Reduced
12
Closed
9
Top Buys
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$419M |
| 2 |
Novavax
NVAX
|
$397M |
| 3 |
Vaxcyte
PCVX
|
$174M |
| 4 |
MacroGenics
MGNX
|
$128M |
| 5 |
Legend Biotech
LEGN
|
$106M |
Top Sells
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$233M |
| 2 |
Exelixis
EXEL
|
$77.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$43.2M |
| 4 |
Gilead Sciences
GILD
|
$41M |
| 5 |
Relmada Therapeutics
RLMD
|
$23.6M |
Sector Composition
| 1 | Healthcare | 93.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $727M | 14.17% | 4,914,955 | – | – |
|
|
FMTX
2
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $419M | 8.16% | +9,011,651 | New | +$419M |
|
|
3
Novavax
NVAX
$1.21B
| $397M | 7.73% | +4,758,833 | New | +$397M |
|
|
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
| $278M | 5.41% | 4,826,910 +650,000 | +16% | +$37.4M |
|
5
TG Therapeutics
TGTX
$4.65B
| $249M | 4.85% | 12,788,457 +2,401,046 | +23% | +$46.8M |
|
|
6
Vaxcyte
PCVX
$4B
| $174M | 3.38% | +5,489,181 | New | +$174M |
|
7
Axsome Therapeutics
AXSM
$6.05B
| $167M | 3.26% | 2,035,132 +131,038 | +7% | +$10.8M |
|
8
Adverum Biotechnologies
ADVM
$64.6M
| $163M | 3.17% | 7,801,641 +528,927 | +7% | +$11M |
|
|
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $135M | 2.62% | 4,681,858 | – | – |
|
|
ADAP
10
Adaptimmune Therapeutics
ADAP
$15.6M
| $131M | 2.55% | 13,052,464 +510,576 | +4% | +$5.11M |
|
|
11
MacroGenics
MGNX
$112M
| $128M | 2.49% | +4,584,652 | New | +$128M |
|
12
Phathom Pharmaceuticals
PHAT
$864M
| $126M | 2.45% | 3,825,008 +117,600 | +3% | +$3.87M |
|
13
Arvinas
ARVN
$568M
| $123M | 2.4% | 3,672,872 | – | – |
|
14
Rhythm Pharmaceuticals
RYTM
$6.85B
| $116M | 2.26% | 5,210,088 -212,224 | -4% | -$4.73M |
|
15
KALA BIO
KALA
$78.8M
| $114M | 2.23% | 10,874,613 | – | – |
|
16
Black Diamond Therapeutics
BDTX
$157M
| $109M | 2.13% | 2,589,904 | – | – |
|
|
17
Legend Biotech
LEGN
$6.41B
| $106M | 2.06% | +2,481,942 | New | +$106M |
|
|
EIDX
18
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $103M | 2.01% | 2,162,671 | – | – |
|
19
Alector
ALEC
$238M
| $101M | 1.97% | 4,127,348 | – | – |
|
|
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
| $99.3M | 1.94% | 3,677,424 -1,598,114 | -30% | -$43.2M |
|
21
Travere Therapeutics
TVTX
$1.56B
| $94.6M | 1.84% | 4,635,687 +469,234 | +11% | +$9.58M |
|
|
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $84.2M | 1.64% | 2,531,445 | – | – |
|
23
Wave Life Sciences
WVE
$1.53B
| $80.9M | 1.58% | 7,775,207 | – | – |
|
|
IGMS
24
DELISTED
IGM Biosciences
IGMS
| $71.7M | 1.4% | 982,723 | – | – |
|
25
Keros Therapeutics
KROS
$618M
| $70.3M | 1.37% | +1,875,000 | New | +$70.3M |
|